Search Results
Your search for ASCO Post,ASCO Post matches 16981 pages
Showing 151 - 200NIAGARA Trial: Perioperative Durvalumab Reduced Risk of Recurrence or Death vs Neoadjuvant Chemotherapy Alone in Muscle-Invasive Bladder Cancer
Positive results from the phase III NIAGARA trial showed perioperative treatment with the PD-L1 blocker durvalumab in combination with neoadjuvant chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival and the key...
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma
In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how to choose among the various doublet immunotherapy options for unresectable hepatocellular...
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial
Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, of Humanitas Cancer Center, Milan, discuss the 5-year overall survival results from the phase III HIMALAYA trial evaluating tremelimumab plus durvalumab in unresectable hepatocellular ...
Immunotherapy and Novel Targeted Drug Appear Beneficial in Women With Early-Stage Gynecologic Disease
Studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 reveal new groups of women with early-stage cervical1 and endometrial cancers2 who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, and a first-in-human study found...
Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers
The results of numerous large international studies reported at the European Society for Medical Oncology (ESMO) Congress 2024 showed that immunotherapy improves long-term overall survival in patients with a variety of cancer types, including advanced melanoma,1,2 triple-negative breast cancer,3...
Nasal and Paranasal Sinus Cancer: Neoadjuvant Chemotherapy and Organ Preservation
Researchers have found that chemotherapy prior to surgery may reduce the amount of normal tissue that needs to be removed in patients with advanced nasal and paranasal sinus squamous cell carcinoma, according to recent findings presented by Saba et al at the European Society for Medical Oncology...
Two Recent Studies Provide Evidence That Breastfeeding After Breast Cancer May Be Safe
Women who breastfeed after treatment for breast cancer—including those with germline BRCA-mutated disease—may not be at increased risk of cancer recurrence or new breast cancers, according to two recent international studies presented by Blondeaux et al (Abstract 1815O) and Peccatori et al...
LEAP-012: Pembrolizumab Plus Lenvatinib Added to TACE Improved Progression-Free Survival in HCC
According to results of the first interim analysis of the phase III LEAP-012 trial, the anti–PD-1 therapy pembrolizumab plus the tyrosine kinase inhibitor lenvatinib, in combination with transarterial chemoembolization (TACE), significantly improved progression-free survival compared with TACE...
FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection
The U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq), including non–small cell lung cancer (NSCLC), small cell lung cancer...
NeoCOAST-2 Trial: Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC
Researchers have demonstrated that the combination of durvalumab with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan may yield high pathologic complete response rates in patients with resectable non–small cell lung cancer (NSCLC), according to findings presented by Cascone et al...
Using TROP2 Expression to Predict Outcomes in Advanced NSCLC
Researchers have uncovered that TROP2 expression as measured by quantitative continuous scoring may be a predictor of clinical outcomes in patients with advanced or metastatic non–small cell lung cancer (NSCLC) treated with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan,...
Study Compares Lung Cancer Screening Triage Protocols
The PanCan nodule management protocol may be superior at triaging lung cancer screening participants compared with the LungRADSv1.1 approach, according to new findings presented by McWilliams et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung...
Perioperative Nivolumab May Improve Event-Free Survival Compared With Neoadjuvant Nivolumab Plus Chemotherapy Alone in Patients With Resectable NSCLC
Adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery may be effective at reducing the risk of disease recurrence or mortality in patients with resectable non–small cell lung cancer (NSCLC) compared with neoadjuvant nivolumab plus chemotherapy alone, according to new...
IASLC Global Survey on Biomarker Testing Reveals Progress and Persistent Barriers in Lung Cancer Biomarker Testing
Despite significant improvements in the perception of biomarker testing compared with a 2018 survey, substantial barriers to implementation may persist globally, according to new findings presented by Smeltzer et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World...
Pathway to Developing Predictive Biomarkers for Immune Checkpoint Inhibitors in NSCLC
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors, according to new findings presented by Kulasinghe et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on...
Youth E-Cigarette Use May Have Declined to Lowest Level in a Decade
A fewer number of U.S. youths have reported current use of e-cigarettes in 2024 compared with 2023, according to new findings published by Park-Lee et al in the Morbidity and Mortality Weekly Report. Background E-cigarettes and nicotine pouches are two categories of tobacco products the U.S. Food...
High Proportion of U.S. Men Older Than 45 Years May Have Misconceptions About Prostate Cancer Screening as Rates of Late-Stage Diagnoses Continue to Rise
Investigators have uncovered misconceptions and gaps in awareness regarding prostate cancer and screening guidelines in light of Prostate Cancer Awareness Month in September, according to a recent survey conducted by The Harris Poll. Background In 2024, an estimated 299,010 men will be diagnosed...
Artificial Intelligence Method Transforms Gene Mutation Prediction in Lung Cancer
Research suggests an artificial intelligence (AI) tool called DeepGEM may provide an advancement in genomic testing that offers an accurate, cost-effective, and timely method for gene mutation prediction from histopathology slides. The research was presented at the International Association for the ...
FDA Approves Ready-to-Use Version of Bortezomib for Subcutaneous Administration
The U.S. Food and Drug Administration (FDA) has approved a new presentation of bortezomib (Boruzu) for ready-to-use subcutaneous or intravenous administration. This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. Bortezomib, a...
How Accurate Is Staging in Early Pancreatic Cancer?
Staging may be inaccurate in up to 80% of patients with early pancreatic cancer, according to a recent study published by Perrotta et al in JAMA. The findings underscored the need for advancements in diagnostic technology and staging, which may help to improve early pancreatic cancer treatment and...
Omitting 5-FU Bolus May Reduce Side Effects in Patients With Gastrointestinal Cancers
Investigators have found that administering fluorouracil (5-FU) through continuous infusion and omitting the bolus component in patients undergoing commonly used treatment regimens targeting metastatic gastrointestinal cancers may improve tolerability without reducing treatment efficacy or...
Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults
Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...
A Diagnosis of Triple-Negative Breast Cancer Was Not on My Radar
Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...
Liquid Biopsy May Predict Risk of Venous Thromboembolism in Patients With Cancer
Researchers have found that a liquid biopsy may help to predict whether patients with cancer may be at risk of developing venous thromboembolism, according to a recent study published by Jee et al in Nature Medicine. Background Liquid biopsy tests—such as MSK-ACCESS—increasingly play a role in...
Can AI Tool Improve Detection of Immune-Related Adverse Events in Patients With Cancer?
Researchers have explored whether an artificial intelligence (AI)-based tool could help to detect immune-related adverse events in patients with cancer, according to a recent study published by Sun et al in the Journal of Clinical Oncology. Background Although immune checkpoint inhibitors can...
Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer
The combination of nivolumab plus gemcitabine/cisplatin chemotherapy achieved high response rates and durable responses and improved overall survival and progression-free survival compared with gemcitabine/cisplatin chemotherapy alone in patients with urothelial carcinoma and clinical evidence of...
Mobile Phones May Not Be Linked to Brain Cancer, WHO-Backed Study Finds
Investigators have found that there may not be an association between mobile phone use and an increased risk of brain cancer, according to a recent World Health Organization (WHO)-commissioned review published by Karipidis et al in Environmental International. Background The WHO and other...
New Study Illuminates Variations in Performance Characteristics Between FIT Tests
Researchers have found substantial variations in the performance characteristics of five commonly used fecal immunochemical tests (FIT), according to a recent study published by Levy et al in the Annals of Internal Medicine. Background Stool-based tests like FIT are currently recommended for...
Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery
In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...
Effect of False-Positives on Adherence to Subsequent Breast Cancer Screening
Patients may be less likely to return for subsequent screening mammography following a false-positive recall for additional imaging or biopsy, according to a recent study published by Miglioretti et al in the Annals of Internal Medicine. The findings raised concerns regarding the potential...
Chronic Conditions Could Delay Lung Cancer Diagnoses
Investigators have revealed that patients with certain chronic conditions may face delays in being diagnosed with lung cancer, according to a recent study published by Rogers et al in the British Journal of Cancer. Background Lung cancer is currently one of the leading causes of cancer-related...
Structural Racism and Cancer Risk From Traffic-Related Air Pollution
Multiple aspects of structural racism may contribute to an increased exposure to carcinogenic traffic-related air pollution, according to a recent study published by White and Ekenga in Cancer. Background High levels of traffic-related air pollutants have been linked to an elevated risk of...
HPV Vaccination Rate Among Young Female Patients With Psychiatric Diagnoses
The rate of human papillomavirus (HPV) vaccination may be lower among female individuals with mental health issues or neurodevelopmental conditions compared with their peers, according to a recent study published by Hu et al in The Lancet Public Health. Background The HPV vaccine is capable of...
Preclinical Study Examines Novel Pancreatic Cancer Treatment
Early-stage research demonstrated the synergistic effects of a novel nanoparticle drug–delivery system to activate an immune pathway in combination with tumor-targeting agents in mice with pancreatic ductal adenocarcinoma, according to a preclinical study published by Chibaya et al in Science...
FDA Approves Cancer Biomarker Test, Companion Diagnostic Indications
The U.S. Food and Drug Administration (FDA) has approved the in vitro diagnostic TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic indications. This targeted sequencing panel interrogates over 500 genes to profile a patient's solid tumor, helping to increase the...
Can a Blood Test Predict Obesity-Related Cancer Risk in Patients With Type 2 Diabetes?
Researchers have found that a blood test may effectively identify patients with type 2 diabetes who may be at a higher risk of developing certain cancers, according to new findings to be presented by Bennetsen et al at the upcoming European Association for the Study of Diabetes Annual Meeting 2024...
Many Women Unaware of Preventive Benefits of Diet for Breast Cancer Risk
Just 28% of U.S. women may be aware that a healthful diet can lower the risk of developing breast cancer, according to a recent survey conducted by the Physicians Committee for Responsible Medicine and Morning Consult. Background The Physicians Committee for Responsible Medicine is a national...
Cancer Has Robbed Me of My Fertility and My Olympic Dreams
I was a track and field athlete throughout college, and my goal was to try out for the Olympics, but cancer had other plans for me. In 2010, while in my senior year in college, I began having sharp, shooting pains in my shoulders, which I initially attributed to overzealous training. But the pain...
Olaparib May Be Effective Without Hormone Therapy in Some Men With Biochemically Recurrent Prostate Cancer
Olaparib may be effective in treating men with biochemically recurrent prostate cancer without accompanying hormone therapy, according to a novel study published by Marshall et al in JAMA Oncology. Background Although most men with localized prostate cancer can be cured with surgery or primary...
Pregnancy-Associated Cancer Incidence and Risks of Adverse Obstetric, Perinatal Outcomes
Women with breast cancer during pregnancy may have a good prognosis and a low risk of adverse obstetric and perinatal outcomes, according to three recent studies published by Lundberg et al in Acta Obstetricia et Gynecologica Scandinavica, Gkekos et al in ESMO Open, and Lundberg et al in Acta...
Disparities in Exposure to Tobacco Content on Streaming Platforms
The risk of encountering tobacco products being advertised, marketed, or promoted on streaming services based on race, ethnicity, socioeconomic status, and smoking habits was identified in a recent study published by Onyeaka et al in JAMA Network Open. Background The World Health Organization...
Early Interventions May Improve Long-Term Academic Achievement in Pediatric Brain Tumor Survivors
Investigators have found that providing early developmental resources may help reduce the adverse effects of brain tumors and cancer therapy on the academic achievement of young pediatric cancer survivors, according to a recent study published by Somekh et al in the Journal of the National Cancer...
Novel Insights Into Multiple Myeloma Progression
Researchers have offered a comprehensive understanding of the progression of multiple myeloma from a treatable condition to a high-risk disease by providing insights into its genetic diversity and subtypes, according to a recent study published by Skerget et al in Nature Genetics. Background...
Targetable Variant Found in Chinese Patients With Ovarian Cancer
Researchers may have uncovered the germline mutational landscape of Chinese patients with ovarian cancer and identified an enriched RAD51D variant in these patients, according to a recent study published by Feng et al in JCO Global Oncology. The findings could serve as a critical reference for...
Can Mindful Breathing Reduce the Intensity of Cancer-Related Pain?
Twenty minutes of mindful breathing, which focuses a person’s attention on their breath, seems to rapidly reduce the intensity and unpleasantness of cancer pain and relieve the associated anxiety, suggest findings from a small comparative study published by Tan et al in BMJ Supportive &...
AI May Help Uncover Relationship Between Radiation Therapy for NSCLC and Cardiac Arrhythmia
Artificial intelligence (AI) tools may be used to better understand the risk of specific cardiac arrhythmias when various parts of the heart are exposed to different thresholds of radiation as part of a treatment plan for non–small cell lung cancer (NSCLC), according to a recent study published by...
Exploring Targeted Therapies in Multiple Myeloma
Investigators have explored the multifaceted nature of multiple myeloma and the potential of targeted therapies to treat patients with the disease, as summarized in a review published by Lu et al in Molecular Biomedicine. Background Multiple myeloma is a complex hematologic malignancy with...
FDA Approves Lazertinib With Amivantamab-vmjw for EGFR-Mutated NSCLC
The U.S. Food and Drug Administration (FDA) has approved the EGFR inhibitor lazertinib (Lazcluze) in combination with the EGFR/MET-targeting bispecific antibody amivantamab-vmjw (Rybrevant) for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer...
Acalabrutinib Plus Chemoimmunotherapy Improves Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Combining Bruton’s tyrosine kinase (BTK) inhibition with chemoimmunotherapy induction significantly extended progression-free survival for older patients with mantle cell lymphoma, and there was also a trend toward improvement on the overall survival benefit, according to data presented during the...
